Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
F Khaznadar, A Petrovic, O Khaznadar… - Journal of clinical …, 2023 - mdpi.com
In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is
the most prevalent liver disease and has become a serious global health problem. To date …
the most prevalent liver disease and has become a serious global health problem. To date …
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
AJ Scheen - Diabetes & metabolism, 2019 - Elsevier
Patients with type 2 diabetes mellitus (T2DM) are exposed to non-alcoholic fatty liver
disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney …
disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney …
An update on the effect of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease: A systematic review of clinical trials
AI Alfayez, JM Alfallaj, MA Mobark… - Current Diabetes …, 2024 - ingentaconnect.com
Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of liver disease,
specifically chronic liver disease. Type 2 diabetes (T2DM) is associated with the risk of …
specifically chronic liver disease. Type 2 diabetes (T2DM) is associated with the risk of …
Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
B Sinha, D Datta, S Ghosal - JGH Open, 2021 - Wiley Online Library
Abstract Background and Aim Sodium glucose cotransporter 2 inhibitors (SGLT‐2i), by way
of their unique mode of action, present an attractive strategy for the treatment of type 2 …
of their unique mode of action, present an attractive strategy for the treatment of type 2 …
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
L Chrysavgis, AM Papatheodoridi… - Journal of …, 2021 - Wiley Online Library
Affecting one fourth of the global population, non‐alcoholic fatty liver disease (NAFLD) is the
commonest chronic liver disorder. It encompasses the simple liver fat accumulation to more …
commonest chronic liver disorder. It encompasses the simple liver fat accumulation to more …
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
FS Coelho, M Borges‐Canha… - Diabetes/metabolism …, 2021 - Wiley Online Library
Aims Non‐alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
[HTML][HTML] Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
A Kontana, K Tziomalos - World Journal of Gastroenterology, 2019 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease
worldwide. NAFLD is considerably more frequent in patients with type 2 diabetes mellitus …
worldwide. NAFLD is considerably more frequent in patients with type 2 diabetes mellitus …
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
ES Makri, A Goulas, SA Polyzos - European Journal of Pharmacology, 2021 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is considered the most prevalent chronic hepatic
disease, as it has been estimated that one of four individuals in the general population has …
disease, as it has been estimated that one of four individuals in the general population has …
[HTML][HTML] SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
R Xu, D Lian, Y Xie, Z Chen, Y Wang, L Mu… - Frontiers in Bioscience …, 2023 - imrpress.com
Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to
accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin …
accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin …
SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection
Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …